artemether/lumefantrine / Generic mfg. - LARVOL DELTA

A Novel Plasmodium falciparum Kelch13 A675T Mutation and High Levels of Chloroquine and Sulfadoxine-Pyrimethamine Resistance in Burundi. (PubMed, medRxiv) - "The pfcrt IET triple mutant haplotype (94.9%) and pfmdr1 N-F-D mutant haplotype (57.9%) indicate sustained CQ resistance and efficacy of artemether-lumefantrine (AL). These findings indicate substantial SP resistance, posing a threat to the efficacy of IPTp and SMC strategies in Burundi. The findings also show potential ART-R and partner drug resistance in Burundi, highlighting the need for strengthened surveillance and coordinated regional efforts to mitigate resistance and sustain malaria control."

Journal • Infectious Disease • Malaria • ABCB1

Efficacy of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine and artesunate-pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in Mozambique, 2022. (PubMed, Malar J) - P4 | "AL and AS-AQ remain effective, as their efficacy remained above the 90% WHO-recommended cut-off. DP and AS-PY also showed therapeutic efficacy above the WHO-acceptable cut-off and could be used as first-line treatments when needed. All four artemisinin-based combinations were well tolerated, with minimal safety concerns."

Journal • Infectious Disease • Malaria

Tracking Plasmodium falciparum antimalarial resistance markers during a malaria pre-elimination period in the Pacific coast of South America. (PubMed, Sci Rep) - "In conclusion, parasites resistant to chloroquine (Pfcrt) and pyrimethamine (Pfdhfr) increased in recent years, while parasites sensitive to sulfadoxine (Pfdhps) and artemisinin (Pfk13) prevail in Ecuador. These results suggest that the current first-line treatment (artemether-lumefantrine + primaquine) is still useful against P. falciparum."

Journal • Infectious Disease • Malaria • ABCB1

Prophylactic and Curative Potency of Xylopia aethiopica "(Dunal) A. Rich." Leaf Extract on Mice Malaria Parasite (Plasmodium berghei). (PubMed, Acta Parasitol) - "The plant extract showed potential early-stage parasite clearance effectiveness and indicated a strong preventive potential against P. berghei infection at the application of the higher dose. The significant parasite clearance observed along with the dose-dependent preventive effect shows that X. aethiopica leaf extract has promising therapeutic and prophylactic potential."

Journal • Preclinical • Infectious Disease • Malaria

Novartis gets approval for first malaria drug for babies and children (Reuters) - " Novartis...opens new tab on Tuesday said it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies and young children."

Approval • Infectious Disease • Malaria

Malaria recrudescence after artemether-lumefantrine treatment in travellers- a hospital-based observational study and literature review. (PubMed, Trop Dis Travel Med Vaccines) - "Recrudescence after AL treatment is rare among travellers, and was associated with diarrhoea, which might cause malabsorption. When recrudescence occurs, retreatment with AL is effective."

Journal • Observational data • Infectious Disease • Malaria

An Unusually Mild Imported Case of Falciparum Malaria That Was Diagnosed and Successfully Treated during Concurrent Acute Leukemia Chemotherapy in Japan. (PubMed, Am J Trop Med Hyg) - "We considered him to be at high risk of severe disease; however, he showed no signs of severe malaria and was treated with 3 days of oral artemether/lumefantrine. The patient's medical history may have contributed to the suppression and successful treatment of falciparum malaria without severe complications."

Journal • Hematological Malignancies • Infectious Disease • Leukemia • Malaria • Oncology

Single low dose primaquine to block the transmission of Plasmodium falciparum-proposed stand-alone and ACT-adapted regimens. (PubMed, BMC Med) - "These regimens offer flexibility for malaria control programmes and guidance for drug manufacturers wishing to co-blister SLDPQ with ACTs. The WHO should reinstate the 3.75 mg tablet for prequalification and determine which regimens should be incorporated into their treatment guidelines to advance malaria elimination."

Journal • Hematological Disorders • Infectious Disease • Malaria • Metabolic Disorders

CYP2B6 * 6 single nucleotide polymorphism among patients with uncomplicated malaria in Adjumani district, Uganda: implications on efficacy of artemether-lumefantrine. (PubMed, medRxiv) - "Interindividual variability in P. falciparum clearance exists, with heterozygous patients demonstrating slow artemether-lumefantrine P. falciparum parasite clearance. There is a need to consider incorporating host genomic factors, such as metabolising enzyme genotype into routine Therapeutic Efficacy Studies (TES)."

Journal • Infectious Disease • Malaria

Malaria: past, present, and future. (PubMed, Signal Transduct Target Ther) - "The FDA-approved regimens like Artemether-Lumefantrine, Atovaquone-Proguanil, and Primaquine are discussed, and their benefits and limitations are highlighted, especially in terms of drug resistance. Perspectives in the development of novel vaccines and new drugs, such as Sevuparin, Imatinib, and Cipargamin, and combination therapies with promise in overcoming resistance has been proposed. Overall, this review provides a detailed summary of the latest progress in malaria research and emphasizes the need for continuous monitoring and innovation in malaria treatment."

Journal • Review • Infectious Disease • Malaria

Antimalarial drug prescriptions and clinical outcomes of febrile children in Arba Minch City, South Ethiopia. (PubMed, Malar J) - "There was a high adherence to guidelines for prescribing antimalarial drugs at both higher- and lower-level healthcare facilities, accompanied by favourable clinical outcomes. However, the proportion of persistent fever and patient visits to other healthcare facilities after initial management underscores the need for additional diagnostic tools, including biomarker assays, to identify bacterial causes of fever."

Clinical data • Journal • Infectious Disease • Malaria

Therapeutic effectiveness and safety of artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 5 to 15 years in three epidemiological strata of malaria in Niger (PubMed, Ann Biol Clin (Paris)) - "No major adverse events were recorded. The results support the use of AL for the treatment of uncomplicated malaria as per the National Malaria Control Program (NMCP)."

Journal • Infectious Disease • Malaria

Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment. (PubMed, Malar J) - "These results support prior studies that suggested: (1) patients given AL and infected with parasites carrying N86 were more likely to experience a recurrent infection; (2) patients given ASAQ and infected with parasites carrying 86Y were more likely to experience a recurrent infection. These findings suggest that ACT and Pfmdr1 genotype may influence outcome after Plasmodium falciparum infection."

Journal • Infectious Disease • Malaria • ABCB1

Malaria after liver transplantation: Report of two cases and a review of published cases. (PubMed, Biomedica) - "Plasmodium vivax was detected in the blood smear, and the patient was treated with artemether/lumefantrine, achieving resolution of the parasitemia. vivax was detected in the blood smear, so treatment with chloroquine and primaquine was started. After treatment, the blood smear was negative, and the patient was discharged."

Journal • Review • Hematological Disorders • Infectious Disease • Malaria • Musculoskeletal Pain • Thrombocytopenia • Transplantation

Slowing the spread of treatment failure to artemisinin-based combination therapies in Uganda. (PubMed, medRxiv) - "We assume that artemether-lumefantrine (AL) will continue to be used in the private sector. A change of first-line therapy from AL to artesunate-amodiaquine (ASAQ) is projected to reduce treatment failures by 34.7% to 38.3% (90% range of simulation outcomes) over six years, while a change to dihydroartemisinin-piperaquine (DHA-PPQ) is projected to reduce treatment failures over the same period by 10.0% to 12.9%...With continued AL use in the private sector, ASAQ and DHA-PPQ deployment in the public sector creates a public-private MFT mix of antimalarial use. DHA-PPQ deployment should be accompanied by real-time molecular surveillance for piperaquine-resistant genotypes."

Journal • Infectious Disease • Malaria

Expansion of the Plasmodium falciparum Kelch13 R622I Mutation in Northwest Ethiopia. (PubMed, Open Forum Infect Dis) - "We conducted a 28-day in vivo efficacy trial of artemether-lumefantrine (Coartem) for treatment of uncomplicated malaria (n = 97) in the Gondar area, northwest Ethiopia, from 2017 to 2018...Further analysis of day 0 samples showed the expansion of a Kelch13 mutation R622I to 9.5% from 2.4% of isolates reported 3 years earlier. Closer examination of the R622I mutation in vitro is warranted."

Journal • Infectious Disease • Malaria

Anti-sporozoite monoclonal antibody for malaria prevention: secondary efficacy outcome of a phase 2 randomized trial. (PubMed, Nat Med) - P2 | "CIS43LS is a long-acting monoclonal antibody specific for the Plasmodium falciparum circumsporozoite protein expressed on sporozoites...At enrollment, all participants received artemether-lumefantrine to clear possible P. falciparum infection...These data indicate that a single dose of anti-sporozoite monoclonal antibodies can achieve durable, sterile protection against P. falciparum infection, underscoring their potential to reduce malaria disease burden and transmission. ClinicalTrials.gov identifier: NCT04329104 ."

Journal • P2 data • Infectious Disease • Malaria

A Case of Severe Plasmodium Falciparum Malaria Treated With Artesunate (ATS 2025) - "Artesunate was continued for 2 days until the parasite burden was <1% on blood smear at which time the patient was transitioned to oral artemether and lumefantrine...Artemisinin derivatives clear parasitemia faster than quinine-based therapies and are associated with lower mortality rates. Notably, P. falciparum artemisinin partial resistance has emerged in Southeast Asia and East Africa, making ongoing research into efficacious treatment for malaria a priority."

Clinical • Cardiovascular • CNS Disorders • Hematological Disorders • Hepatology • Hypoglycemia • Hypotension • Infectious Disease • Malaria • Metabolic Disorders • Renal Disease • Respiratory Diseases • Thrombocytopenia

Cerebral Malaria: A Case of Morbid Rise in Parasitemia (ATS 2025) - "He presented to his PCP's office where malaria smear was ordered and Coartem prescribed, however not readily available in the area...IV doxycycline and ceftriaxone started in absence of first line treatment... This case illustrates how a rare presentation of non-pediatric cerebral malaria with significant parasitemia caries high probability of mortality without access to proper treatment. Measures should be taken to ensure availability of first line agents."

Clinical • CNS Disorders • Cough • Infectious Disease • Malaria • Pediatrics • Respiratory Diseases

A Case of Severe Malaria With Cerebral Involvement Manifesting as Encephalopathy and Multiorgan Dysfunction (ATS 2025) - "She was treated with intravenous (IV) artesunate and oral artemether/lumefantrine, with rapid reduction of parasite load to 0.1% and eventual complete neurologic recovery. Our case represents a severe presentation of a rare disease in the United States, and highlights the necessity of careful history taking, prompt diagnosis and patient education regarding the necessities of chemoprophylaxis when traveling to malaria-endemic areas."

Clinical • Anemia • CNS Disorders • Hematological Disorders • Infectious Disease • Malaria • Rare Diseases • Renal Disease • Thrombocytopenia

Thrombotic Thrombocytopenic Purpura Associated With Plasmodium Falciparum: A Case Report Highlighting Diagnostic Dilemmas (ATS 2025) - "The patient was treated with artemether-lumefantrine, resulting in improved parasitemia...Clinicians, especially in regions where malaria is endemic, should be vigilant in monitoring for atypical presentations and act swiftly when symptoms align with TTP criteria. This case underscores the importance of maintaining a high index of suspicion for TTP in patients with malaria, advocating for early intervention, including plasma exchange, even in the absence of definitive diagnostic confirmation."

Case report • Clinical • Acute Kidney Injury • Anemia • Hematological Disorders • Infectious Disease • Malaria • Nephrology • Renal Disease • Thrombocytopenic Purpura

Healthcare Mishaps and a Fatal Case of Cerebral Malaria (Plasmodium Falciparum and Ovale) (ATS 2025) - "This patient was not treated with IV artesunate (first line therapy) due to inability of hospital procurement but was treated with second line artemether-lumefantrine and primaquine. This case report discusses both the medical aspects and ethical aspects of treating severe malaria in the critical care setting. This patient ultimately died within 24 hours of presentation to the hospital."

Clinical • Acute Kidney Injury • Acute Respiratory Distress Syndrome • Anemia • CNS Disorders • Epilepsy • Hematological Disorders • Hepatology • Infectious Disease • Malaria • Metabolic Disorders • Musculoskeletal Pain • Nephrology • Pain • Renal Disease • Respiratory Diseases

MALARIA IN CHILDREN ADOPTED FROM THE DEMOCRATIC REPUBLIC OF CONGO (ESPID 2025) - "Children infected with P.vivax or P.ovale received primaquine. Although urine and blood cultures were sterile, four children received ceftriaxone due to elevated inflammatory markers...In the arriving country, malaria recurrence can occur due to recrudescence. Non-severe cases should be treated with an oral combination of artemether and lumefantrine, however, medication intolerance may occur requiring the administration of artesunate."

Clinical • Infectious Disease • Malaria

ACUTE ACALCULOUS CHOLECYSTITIS AND POST-ARTESUNATE HEMOLYTIC ANEMIA: TWO RARE COMPLICATIONS IN SEVERE MALARIA (ESPID 2025) - "Because of palpable liver enlargement, an ultrasound was performed revealing acalculous cholecystitis and cholangitis (image 1), prompting a switch from ceftriaxone to cefotaxime. She completed 48 hours of artesunate followed by 72 hours of artemether-lumefantrine...Ultrasound with doppler: acute acalculous cholecystitis Learning Points/Discussion Acute acalculous cholecystitis associated with malaria is extremely rare, likely under-reported, but typically does not lead to long-term complications. Post-artesunate hemolytic anemia is an uncommon but potentially catastrophic complication, highlighting the importance of short-term follow-up in these patients."

Infectious Disease • Malaria

SEVERE MALARIA IN A PEDIATRIC PATIENT: FROM HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS TO IMMUNE HEMOLYTIC ANEMIA (ESPID 2025) - "After initiating treatment with artemether-lumefantrine, on the 4 th day of evolution, despite decreasing parasitemia (0,8%), he developed hypotension with tachycardia, pancytopenia, massive splenomegaly, increased ferritin, hypertriglyceridaemia and elevated soluble CD25 were observed, fulfilling criteria for HLH...He was treated with external heating, warmed circuits and transfusional support, as well as methylprednisolone with a good clinical response, being discharged 12 days after admittance, without any known relapses. Learning Points/Discussion This case highlights the importance of early recognition of severe malaria complications, such as HLH and AIHA, as well as the role of corticosteroid therapy in improving outcomes in complex cases."

Clinical • Infectious Disease • Malaria • HP • IL2RA